Search Within

Benjamin Heath Durham

Formats
  1. Journal Article (56)
  2. Meeting Abstract (50)
  3. Research Letter (3)
  4. Review (3)
  5. Correspondence (2)
  6. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (100)
  2. Department of Medicine (99)
  3. Hematologic Malignancies, Division of (99)
  4. GSK Faculty (95)
  5. Executive Committee, Center for Hematologic Malignancies (94)
  6. Tow Center for Developmental Oncology (TCDO) (84)

More Groups

People
  1. Omar Abdel-Wahab (83)
  2. Eli Diamond (61)
  3. Ahmet Dogan (25)
  4. Raajit Rampal (24)
  5. David Hyman (20)
  6. Kseniya Petrova-Drus (19)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (13)
  4. 2022 (9)
  5. 2021 (7)
  6. 2020 (8)

More Years

Publications
  1. Blood (35)
  2. Pediatric Blood and Cancer (12)
  3. Laboratory Investigation (5)
  4. Modern Pathology (5)
  5. Cancer Discovery (4)
  6. Leukemia (4)

More Publications

Publishers
  1. American Society of Hematology (38)
  2. Nature Publishing Group (19)
  3. Wiley Periodicals, Inc (12)
  4. American Association for Cancer Research (7)
  5. Nature Research (5)
  6. Cell Press (3)

More Publishers

Results (115)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia
    Journal Article

    Park, J. H.; Devlin, S.; Durham, B. H.; Winer, E. S.; Huntington, S.; von Keudell, G.; Vemuri, S.; Shukla, M.; Falco, V.; Cuello, B.; more...
    NEJM Evidence (2023)

    Fulltext@MSK | Save
  • CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
    Research Letter

    Diamond, E. L.; Francis, J. H.; Lacouture, M. E.; Rotemberg, V.; Yabe, M.; Petrova-Drus, K.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H.
    Leukemia (2023)

    Fulltext@MSK | Save
  • Overcoming barriers to tumor genomic profiling through direct-to-patient outreach
    Journal Article

    Doe-Tetteh, S. A.; Camp, S. Y.; Reales, D.; Crowdis, J.; Noronha, A. M.; Wolff, B.; Alano, T.; Galle, J.; Selcuklu, S. D.; Viale, A.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Clonal characterization and somatic hypermutation assessment by next-generation sequencing in chronic lymphocytic leukemia/small lymphocytic lymphoma: A detailed description of the technical performance, clinical utility, and platform comparison
    Journal Article

    Petrova-Drus, K.; Syed, M.; Yu, W.; Hutt, K.; Zlotnicki, A. M.; Huang, Y.; Kamalska-Cyganik, M.; Maciag, L.; Wang, M.; Ma, Y. G.; more...
    Journal of Molecular Diagnostics (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Efficacy of alpelisib in PI3K-driven langerhans cell histiocytosis
    Meeting Abstract

    Mazor, R. D.; Durham, B. H.; Abdel-Wahab, O. I.; Diamond, E. L.; Yabe, M.; Itchaki, G.; Ben-Sasson, M.; Hershkovitz-Rokah, O.; Shpilberg, O.
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • A multinational series of 26 patients with mixed histiocytic neoplasms highlighting a diverse mutational landscape and superior efficacy of targeted therapies
    Meeting Abstract

    Diamond, E. L.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Ulaner, G. A.; Reddy, R.; Lacouture, M. E.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • ALK-positive histiocytosis: A new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
    Journal Article

    Kemps, P. G.; Picarsic, J.; Durham, B. H.; HeĢlias-Rodzewicz, Z.; Hiemcke-Jiwa, L.; van den Bos, C.; van de Wetering, M. D.; van Noesel, C. J. M.; van Laar, J. A. M.; Verdijk, R. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • RAF-Independent MEK mutations drive histiocytic neoplasms in vivo and are sensitive to single-agent ERK inhibition in patients
    Meeting Abstract

    Durham, B. H.; Singer, M. E.; Benbarche, S.; Erickson, C.; Rahman, J.; Solit, D. B.; Witkowski, M.; Rosen, N.; Abdel-Wahab, O.; Diamond, E. L.
    Blood (2022)

    Fulltext@MSK | Save